| First Author | Hoh Kam J | Year | 2015 |
| Journal | Exp Eye Res | Volume | 135 |
| Pages | 59-66 | PubMed ID | 25921262 |
| Mgi Jnum | J:230331 | Mgi Id | MGI:5758784 |
| Doi | 10.1016/j.exer.2015.03.023 | Citation | Hoh Kam J, et al. (2015) Topical cyclodextrin reduces amyloid beta and inflammation improving retinal function in ageing mice. Exp Eye Res 135:59-66 |
| abstractText | Retinal ageing results in chronic inflammation, extracellular deposition, including that of amyloid beta (Abeta) and declining visual function. In humans this can progress into age-related macular degeneration (AMD), which is without cure. Therapeutic approaches have focused on systemic immunotherapies without clinical resolution. Here, we show using aged mice that 2-Hydroxypropyl-beta-cyclodextrin, a sugar molecule given as eye drops over 3 months results in significant reductions in Abeta by 65% and inflammation by 75% in the aged mouse retina. It also elevates retinal pigment epithelium specific protein 65 (RPE65), a key molecule in the visual cycle, in aged retina. These changes are accompanied by a significant improvement in retinal function measured physiologically. 2-Hydroxypropyl-beta-cyclodextrin is as effective in reducing Abeta and inflammation in the complement factor H knockout (Cfh(-/-)) mouse that shows advanced ageing and has been proposed as an AMD model. beta-cyclodextrin is economic, safe and may provide an efficient route to reducing the impact of retinal ageing. |
